论文部分内容阅读
目的:评价卡培他滨单药治疗局部晚期乳腺癌的疗效及毒副作用。方法:24例局部晚期乳腺癌患者给予卡培他滨2500mg·m~(-2)·d~(-1),连用2周,每3周为1个周期,常规治疗6～8周期,有严重毒副作用者需停药或减量。结果:肿瘤完全缓解(CR)2例,部分缓解(PR)9例,稳定(SD)10例,进展(PD)3例。总有效率为45.8%主要不良反应为手足综合征,经调整剂量可缓解。结论:卡培他滨单药治疗局部晚期乳腺癌疗效确切,安全性较高,可作为局部晚期乳腺癌的一线治疗药物。
Objective: To evaluate the curative effect and side effects of capecitabine in the treatment of locally advanced breast cancer. Methods: Twenty-four patients with locally advanced breast cancer received capecitabine 2500 mg · m ~ (-2) · d ~ (-1) for 2 weeks, once every 3 weeks and routinely treated for 6 to 8 cycles Serious side effects need to be discontinued or reduced. Results: There were 2 patients with complete remission (CR), 9 with partial response (PR), 10 with stable (SD) and 3 with progression (PD). The total effective rate was 45.8% The main adverse reactions were hand-foot syndrome, adjusted dose can be alleviated. Conclusion: Capecitabine monotherapy for the treatment of locally advanced breast cancer is effective and safe, and can be used as a first-line treatment for locally advanced breast cancer.